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Abstract
Background: Paget's disease of bone (PDB) is characterised by focal increases in bone turnover,
affecting one or more bones throughout the skeleton. This disrupts normal bone architecture and
causes pain, deformity, deafness, osteoarthritis, and fractures.
Genetic factors are recognised to play a role in PDB and it is now possible to carry out genetic
tests for research. In view of this, it is timely to investigate the clinical potential for a programme
of genetic testing and preventative treatment for people who have a family history of PDB, to
prevent or delay the development of PDB.
Evidence from non-genetic conditions, that have effective treatments, demonstrates that patients'
beliefs may affect the acceptability and uptake of treatment. Two groups of beliefs (illness and
treatment representations) are likely to be influential.
Illness representations describe how people see their illness, as outlined in Leventhal's Self-
Regulation Model. Treatment representations describe how people perceive potential treatment
for their disease. People offered a programme of genetic testing and treatment will develop their
own treatment representations based on what is offered, but the beliefs rather than the objective
programme of treatment are likely to determine their willingness to participate. The Theory of
Planned Behaviour is a theoretical model that predicts behaviours from people's beliefs about the
consequences, social pressures and perceived control over the behaviour, including uptake of
treatment.
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Methods/design: This study aims to examine the acceptability of genetic testing, followed by
preventative treatment, to relatives of people with PDB. We aim to interview people with Paget's
disease, and their families, from the UK. Our research questions are:
1. What do individuals with Paget's disease think would influence the involvement of their
relatives in a programme of genetic testing and preventative treatment?
2. What do relatives of Paget's disease sufferers think would influence them in accepting an offer
of a programme of genetic testing and preventative treatment?
Discussion: Our research will be informed by relevant psychological theory: primarily the Self-
Regulation Model and the Theory of Planned Behaviour. The results of these interviews will inform
the development of a separate questionnaire-based study to explore these research questions in
greater detail.
Background
The need for this research
Over recent years, advances in human molecular genetics
have resulted in the identification of polymorphisms and
mutations in several genes that cause or predispose to dis-
eases such as cancer, neurodegenerative conditions and
inborn errors of metabolism. For some of these condi-
tions, such as Huntington's disease and muscular dystro-
phy, it is possible to offer a genetic test that will give
information on the probability of the disease occurring
but this is somewhat unattractive to patients without the
prospect of an effective treatment. For other diseases, such
as hypercholesterolaemia and haemochromatosis, identi-
fication of genetic susceptibility can be used as a risk fac-
tor to inform management strategies and treatment
decisions in a similar way to other clinical risk factors.
This application aims to test the feasibility of translating
genetic knowledge into practice by examining the accept-
ability of offering genetic testing, followed by therapeutic
intervention, to people with Paget's disease of bone.
Paget's disease of bone
Paget's disease of bone (PDB) affects about 3% of individ-
uals over the age of 55 years in the UK [1]. It is character-
ised by focal increases in bone turnover, affecting one or
more bones throughout the skeleton. The abnormal bone
turnover disrupts normal bone architecture and causes
bone pain, bone deformity, deafness, osteoarthritis, and
pathological fractures [2]. Genetic factors have long been
recognised to play an important role in Paget's disease [3-
6] and recent studies by our own group and others indi-
cate that between 40–50% of instances of familial Paget's
disease are caused by mutations affecting the ubiquitin-
associated (UBA) domain of the SQSTM1 gene [7-11].
Genotype-phenotype analysis has shown that SQSTM1
mutations are highly penetrant, such that between 90–
100% of individuals within families who carry mutations
will have developed the disease by the age of 65 years [7-
11].
In view of this, it is timely to investigate the clinical poten-
tial for a programme of genetic testing and preventative
treatment for patients who carry SQSTM1 mutations, in
an effort to prevent or delay the development of Paget's
disease or its complications.
Prospects for preventing Paget's disease
Bisphosphonates such as Risedronate, Pamidronate and
Zoledronate have emerged as highly effective agents for
reducing bone turnover and treating bone pain in patients
with Paget's disease [12]. Clinical studies have shown that
these drugs can restore elevated levels of bone turnover to
normal in a high proportion of cases, can improve the
appearance of Pagetic lesions on isotope bone scans [13],
and can restore bone architecture to normal, as assessed
histologically [14].
This raises the possibility that patients who carry SQSTM1
mutations and who are at high risk of developing Paget's
disease could be offered prophylactic therapy, in an
attempt to prevent the disease occurring, or to prevent
complications developing. A particularly promising mode
of treatment in this respect is Zoledronate, which is a
highly effective treatment for Paget's disease even in
microgram doses [15], with inhibitory effects on bone
turnover that can extend for at least 12 months after a sin-
gle injection [16]. There is also evidence to suggest that
treatment with intravenous Pamidronate and oral Risedr-
onate can suppress bone resorption in active Paget's dis-
ease for up to two years [17,18].
With the existence of effective treatment for Paget's dis-
ease that could prevent or delay the onset of the disease,
we need to explore the acceptability of genetic testing fol-
lowed by preventative treatment in patients with Paget's
disease of bone.BMC Health Services Research 2006, 6:71 http://www.biomedcentral.com/1472-6963/6/71
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Possible factors that could affect acceptability of genetic 
testing and preventative treatment
Evidence from other areas of genetic testing suggests that
patients may not wish to take genetic tests. For example,
in Huntington's disease, prior to the development of a
genetic test, individuals at risk declared a much higher
intention of taking a test than the actual numbers taking
the test when it became available [19]. Studies have
shown that there is a widespread belief that genetic condi-
tions are not treatable. Such beliefs might affect the
acceptability of diagnosis and treatment of genetic condi-
tions. However, the additional offer of effective preventa-
tive treatment can make genetic testing more acceptable
[20].
Beliefs
Evidence from other, non-genetic, conditions, for which
there are effective treatments, demonstrates that patients'
beliefs may affect the acceptability and uptake of treat-
ment. Two groups of beliefs (illness representations and
treatment representations) are most likely to be influen-
tial.
Illness representations
Illness representations describe how people see their ill-
ness. This is most clearly outlined in the Self-regulation
Model (SRM) [21]. The five key representations are:
• identity (e.g. the 'label', identifying symptoms);
• cause (e.g. stress, genetics);
• consequences (e.g. activity limitations, loss of wages);
• timeline (e.g. acute, fluctuating, progressing);
• cure/control (e.g. medication, diet, exercises).
In addition, the SRM identifies the emotional representation
(e.g. frustrating, frightening) as a separate dimension of
representation. Based on this model, Weinman and col-
leagues [22] have developed a measure, the Illness Percep-
tions Questionnaire (IPQ), to assess these representations
and have found that they are predictive of uptake and
response to a wide variety of treatments, including the
bone disease Rheumatoid Arthritis [23]. Clearly, such
beliefs may influence uptake of a new treatment offered to
families with Paget's disease, and Marteau has shown that
beliefs affect the decision to accept a genetic test [24].
Paget's disease has a highly variable presentation: age at
onset, severity of symptoms and impact on sufferer's lives;
and individuals might vary in their response to an offer of
testing and treatment depending on the disease history
within their family. Using the World Health Organisation
International Classification of Functioning, Disability and
Health model of health components [25], one might
expect that all three components (impairment, activity
limitations, and participation restrictions) might affect
beliefs about the identity, consequences and timeline of
the condition.
Treatment representations
Treatment representations describe how people perceive
potential treatments for their disease. There is considera-
ble evidence that patients' beliefs about treatment (e.g.
accessibility, burden, perceived likelihood of success)
influence uptake and adherence [26]. People offered a
programme of genetic testing and treatment will develop
their own treatment representations based on what is
offered, but the beliefs rather than the objective pro-
gramme of treatment, are likely to determine their willing-
ness to participate. The Theory Of Planned Behaviour
(TPB) [26] (is a theoretical model, which predicts behav-
iours from people's beliefs about the consequences, social
pressures and perceived control over the behaviour,
including uptake of treatment (Figure 1).
The nature of the treatment and treatment offer
The nature of the treatment, and the way in which the
treatment is offered, may affect acceptability. One needs
to consider not only how to invite the affected individual
to 'involve' their family, but also how to introduce the
programme to invited family members. Hardeman and
colleagues [27] in the Pro-Active Programme, have devel-
oped an interview for families of people with Type 2 dia-
betes that incorporates the offer of the intervention for
offspring. This interview was based on the interviews used
to develop questionnaires for the Theory of Planned
Behaviour (TPB) addressing beliefs about involving the
offspring in the programme. It has proved very effective in
rendering the programme acceptable [27].
The Theory of Planned Behaviour (Azjen, 1991) Figure 1
The Theory of Planned Behaviour (Azjen, 1991).
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In addition, the treatment offered for Paget's disease could
be in tablet or infusion form, and could be administered
in a range of environments. All of these factors may influ-
ence the acceptability of a programme of genetic testing
and preventative treatment.
Demographic and health characteristics
Demographic and health characteristics may also influ-
ence the acceptability of treatment. For example, someone
who is older may think they are less at risk if they have
passed the age of onset of Paget's disease in the affected
person; or they may think they are nearing the time when
the disease might affect them. Closeness to the affected
person may make them view the condition as more or less
serious, and they may be influenced by how the affected
person copes with the illness. Furthermore, one might
expect there to be more agreement within members of one
family than between families due to their shared exposure
to the condition as well as their opportunity to discuss
and influence each other.
Scientific value of this study
This project takes advantage of recent advances in knowl-
edge about the molecular-genetic basis of PDB, with
advances in therapeutics to address an important clinical
question that is of relevance to patients with Paget's dis-
ease and their families. The project provides added value
in that modern techniques in behavioural science will be
applied to a specific issue in the treatment of Paget's dis-
ease, while at the same time investigating more general
theories of human behaviour. Using the Self-Regulation
Model, we will investigate how genetic information and
preventive opportunities affect self-regulation via illness
representations and, using the Theory of Planned Behav-
iour, how uptake of the offer of genetic testing and treat-
ment is predicted by the constructs found to predict
behaviour in other settings. Thus the findings will be rele-
vant to these theories. They will also contribute to ongo-
ing work to integrate these two models in understanding
behaviour related to illness.
In addition, the knowledge gained from this investigation
would be relevant to other musculoskeletal diseases such
as osteoporosis, which also have a strong genetic compo-
nent, and which can be prevented by bisphosphonates
and hormone replacement therapy. With completion of
the human genome project, and advances in human
molecular genetics, it is probable that DNA testing with
single genetic markers or combinations of markers will be
offered for a wide range of other chronic diseases for
which effective treatments are available. The results of the
present research project will also be of direct relevance to
the development of programmes of genetic testing and
preventative intervention for these conditions.
Study aim
The aims of the GaP study are to understand factors that
might influence the acceptability of an offer of a pro-
gramme of genetic screening and preventative treatment
to families of Paget's disease sufferers.
The specific research questions are:
1.  a) What do individuals with Paget's disease think
would influence the involvement of their relatives in a
programme of genetic testing and preventative treatment?
and;
b) What do relatives of Paget's disease sufferers think
would influence them in accepting an offer of a pro-
gramme of genetic testing and preventative treatment?
2. Do the following factors affect acceptability of a pro-
gramme of genetic testing and preventative treatment in
relatives of Paget's disease sufferers?
• Illness and emotional representations of Paget's disease;
• Treatment representations;
• Presentation of the disease in affected relative(s) (age at
onset, impairment, activity limitations, participation
restrictions; family history as a function of the number of
affected relatives and the relationship to the Subject);
• Respondent characteristics (age, gender and health);
• Beliefs of other family members; and
• The nature of the treatment offered.
By answering these research questions, this study will cast
light on the feasibility of developing a programme of
genetic testing and preventative treatment for individuals
who carry SQSTM1  mutations that are at high risk of
developing Paget's disease. Since we do not yet know
whether prophylactic bisphosphonate therapy would be
effective in preventing Paget's disease or its complications,
we envisage that the results of the present study would be
used to inform the design of a randomised controlled trial
to investigate the efficacy of prophylactic bisphosphonate
therapy in people with SQSTM1 mutations. Such a study
would form the topic of a future research project.
An overview of the GaP study
The GaP study has two stages:
Stage 1: This part of the study will address the first research
question and aims to identify factors that would influence
involvement of relatives not known to have Paget's dis-BMC Health Services Research 2006, 6:71 http://www.biomedcentral.com/1472-6963/6/71
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ease in a programme of genetic screening and preventative
treatment.
Stage 2: This part of the study is not part of the current pro-
tocol, and will comprise a postal questionnaire study of
people without Paget's disease but who are relatives of
people with Paget's disease.
Methods/design for stage 1
Stage 1 will employ semi-structured interviews with indi-
viduals suffering from Paget's disease, and their relatives
who have not been diagnosed as suffering from Paget's
disease. The results of Stage 1 will inform the develop-
ment of a TPB-based questionnaire for Stage 2.
The interviews with individuals suffering from Paget's dis-
ease will use the Theory of Planned Behaviour (TPB)-
based [26].
Subjects and recruitment
Individuals with Paget's disease will be identified from an
established cohort: The PRISM trial.
The PRISM cohort involves 1331 patients with Paget's dis-
ease. The PRISM trial involves 39 collaborating centres
ranging in size from 3 trial participants to approx 250 trial
participants.
For this part of the study we will identify potential partic-
ipants from 7 centres collaborating in the PRISM trial.
Identifying subjects
A purposive sample of individuals with Paget's disease
identified from the PRISM study will be invited to partici-
pate. Participating individuals will be asked to identify
first and second-degree relatives without Paget's disease
who they think might also be interested in taking part in
the study. These individuals will be invited to participate
in separate interviews. Relatives identified by this proce-
dure will be selected for the study to represent a range of
family relationships (e.g. siblings, children, grandchil-
dren) and living conditions (e.g. living in same house,
nearby, or far away). A sequential approach to sampling
will therefore be used.
For this stage of the study, individuals will be approached
from a restricted selection of PRISM centres (Table 1.).
These 3 groups of centres represent regions of the UK with
varying incidences of Paget's disease. A low incidence of
Paget's disease occurs in Scotland, whereas Manchester
and Liverpool are well recognised as areas of high inci-
dence of Paget's disease. Lancashire is considered to be the
global 'hotspot' for Paget's. The southern England region
represents an area with an incidence rate between those of
the northern England and Scottish regions.
Contacting subjects
A letter will be sent to probands inviting them to partici-
pate in an interview together with study information leaf-
lets. The letter will include a 'tear off' section to return (in
a reply paid envelope) if they are interested in discussing
the study further. Probands will also be asked to provide
contact details of one or two relatives who may also like
to participate in an interview.
A letter will be sent to relatives identified by probands
inviting them to participate in an interview together with
study information leaflets. The letter will include a 'tear
off' section to return (in a reply paid envelope) if they are
interested in discussing the study further.
A researcher will telephone those who return the slip, and
who are interested in taking part, to discuss the study fur-
ther. If the person is still interested, an appropriate time
and place for interview, and arrangements for formal con-
sent will be discussed. There will be no follow-up of those
probands or relatives that decline to participate or who do
not reply.
A Thank You letter will be sent to probands and relatives
taking part in Stage 1, once each individual interview is
completed.
Sample size
Sampling will continue until saturation, i.e. no 'new' ideas
are being introduced within the three TPB beliefs (behav-
ioural, normative and control) and 5 SRM domains (iden-
tity, cause, consequences, cure/control, timeline) plus
emotional representations). It is expected that this will
involve 10–20 individuals from the PRISM cohort
together with 10–20 relatives of these affected individuals.
Purposive sampling will be used to identify probands and
relatives to be approached for participation in this stage.
Table 1: The pool of probands available for the study, and their geographical location.
Pool of probands available (approx.)
1. Scotland – Aberdeen/Dundee 75
2. Northern England – Manchester/Sheffield/Keighley 160
3. Southern England – London/Southampton 30BMC Health Services Research 2006, 6:71 http://www.biomedcentral.com/1472-6963/6/71
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Subjects are not chosen at random but instead are chosen
because they are expected to facilitate investigation of the
range of views and opinions relevant to the research. The
aim of sampling is therefore to maximise variety for anal-
ysis. Subjects will be purposively selected to include a
good spread across the following factors:
Probands
• Gender (male, female);
• Age (<40 years, 41–60 years, >61 years);
• Severity of disease (monostotic, polyostotic);
• Time elapsed since diagnosis (<5 years, > 5 years); and
• Family history (Yes, No).
Relatives
• Gender (male, female);
• Age (<40 years, 41–60 years, >61 years);
• Severity of disease in proband (monostotic, polyos-
totic);
• Relationship to proband (parent, sibling, grandparent,
aunt/uncle); and
• Living proximity to proband (within 50 miles, further
than 50 miles).
Anne Langston will undertake selection of interviewees,
and the interviewer (Clare Robertson) will be blinded to
these details.
Exclusion criteria
Exclusion criteria include:
• Known* limited life expectancy (under one year); or
• Aged less than 18 years.
* The caveat of 'known' is used, as it may not be possible to
determine limited life expectancy of relatives.
A lower age limit has been imposed (minimum age of 18
years). Clinical studies suggest that people with SQSTM1
mutations develop Paget's disease from approximately 45
years of age onwards [9]. Clinical intuition would suggest
that starting a programme of preventative treatment at age
40 years would be therefore be appropriate. However, the
clinical evidence to support this is still lacking. In addi-
tion, it is likely that a psychologically 'acceptable' age for
beginning preventative treatment will differ from that
indicated by existing evidence. As such, we propose to
include all adult relatives of probands to determine the
effect of age of the acceptability of genetic testing, and pre-
ventative treatment.
Special arrangements for including people with specific 
communication needs
We have not made special arrangements for non-English
speaking subjects for two reasons:
A model of the relationship between explanatory and dependent variables Figure 2
A model of the relationship between explanatory and dependent variables.
Treatment
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experience of PDB 
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1. Providing multi-lingual facilities for this small number
of interviews will be logistically and financially prohibi-
tive;
2. Paget's disease is rare in non-Caucasians and therefore
we anticipate that English will be the first language of the
majority of eligible individuals within the UK.
3. It has not proved necessary to provide special arrange-
ments for participants of the PRISM trial, and therefore it
is not anticipated that the requirement will exist for this
study.
Participants whose first language is not English will not
automatically be excluded from the study if they are either
able to communicate in English, or an interpreter is avail-
able to assist with communication. Such arrangements
will be accommodated, if it is practicable to do so, on an
individual basis.
Individuals with limited life expectancy are excluded from
Stage 1 of the study as the interview process may be cog-
nitively and emotionally taxing for them.
Individuals with known limited hearing ability may be
excluded from Stage 1 due to practical difficulties of carry-
ing out an interview and the distress and frustration this
may cause the participant. If a participant is deaf but can
lip-read, or has a friend or family member who can use
Sign Language for them, the individual will not be
excluded. Since deafness caused by Paget's disease of the
skull is an important complication of Paget's disease,
every attempt will be made to include these individuals in
Stage 1 of the study, where practicable and where it will
not cause distress to the participant.
Information leaflets and consent forms will be made
available in large print upon request.
Setting
For Stage 1, identified PRISM probands and relatives will
be invited to interview at home or in a convenient clinical
or research environment. The place of the interview will
be according to the subject's preference. Travel expenses
incurred by the subject will be reimbursed. Interviews will
be tape-recorded and will be conducted face-to-face to
allow the interviewer to counsel for consent.
Consent process
Consent will be sought at interview and participating
probands and relatives will be asked to sign a consent
form. One copy will be kept by the participants and one
returned to the researcher.
The consent form has been designed in accordance with
current ethical good practice [28]. The consent form
explicitly states that genetic testing is not available as part
of this study.
Withdrawal of subjects
Individuals will be able to withdraw from the process at
any time. If individuals wish to withdraw their consent
after the interview has taken place, the audio recording
and any associated transcript will be destroyed if specifi-
cally requested. They will not be contacted for participa-
tion in Stage 2 or future research.
Measures
Semi-structured interview schedules will be developed to
address Behavioural, Normative and Control beliefs using
the TPB preliminary interview format [26,29], and for
probands will also address illness perceptions using an
interview schedule based on the IPQ format [22].
For probands, the interview will also address barriers and
facilitators to inviting their non-Pagetic relatives to partic-
ipate in interviews about genetic testing and preventative
treatment (a topic guide will be used). For non-Pagetic rel-
atives, the interview will address barriers and facilitators
to participating in a programme of genetic testing and pre-
ventative treatment (a topic guide will be used).
Data recording
With the permission of the subject, the entire interview
will be digitally audio recorded. The subject will be
assigned an anonymous code (study number). Audio
recordings will be labelled with the date of interview and
study number.
Not all of the interviews will be transcribed. Transcription
will occur on a limited selection of interviews (maximum
of 5) to allow more detailed analysis. When transcription
does take place it will be carried out by a trained data tran-
scriber (not the interviewer). Pauses, including 'hmmms'
and 'ahs', and interruptions of one speaker by another will
also be indicated in the transcription. Transcribed inter-
views will be reviewed by the interviewer responsible for
data collection (with reference to the original recording)
and transcription errors will be rectified. Transcriptions of
interviews will follow recognised guidelines and will not
include any identifying information.
Analysis
Data will be content-analysed using simple TPB & IPQ
coding frameworks. A sequential approach to sampling
will be used whereby data will be analysed throughout
recruitment on an ongoing basis until either the point of
data saturation is reached (where no new responsesBMC Health Services Research 2006, 6:71 http://www.biomedcentral.com/1472-6963/6/71
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emerge) or a maximum of 20 probands and 20 relatives
have been interviewed.
End of study procedures
During the consent process for the study we will ascertain
whether participants would like to be sent a report of the
study results. For those participants indicating that they
would like study results, a short report will be prepared
and circulated at the end of the study.
Once the interview is completed the participant will be
sent a Thank You letter. This will include a tear-off reply
slip that participants will be asked to return indicating
whether or not they would like to participate in Stage 2 of
the GaP study.
Confidentiality
Transcripts and audio recordings will be kept in separate
locked filing cabinets, and destroyed after 20 years in
accordance with current MRC guidelines.
The Study Office, based in the Health Services Research
Unit (HSRU), is responsible for the confidentiality of all
study records. In accordance with the HSRU code of con-
duct, all data will be password protected against unau-
thorised access and stored in accordance with the Data
Protection Act 1998. All stored data will be anonymised.
Finance and indemnity
The study is supported by a grant from the Medical
Research Council (MRC). The University of Aberdeen
holds the grant, and has accepted Sponsorship responsi-
bilities for the study, including indemnity for negligent
and non-negligent harm.
Reporting and dissemination
A summary of the results of the study will be prepared and
distributed, not only to the appropriate funding body, but
also to all subjects who take part (if they so wish). Results
will be published in peer-reviewed academic journals.
Abbreviations
DNA Deoxyribonucleic acid. The substance that makes up
genes.
Familial Paget's disease Paget's disease that affects more
than one member of a family
IPQ-R The Illness Perceptions Questionnaire (R stands for
revised version). This measures what people think about
an illness in themselves or others.
MRC  Medical Research Council. A UK government
funded organisation that supports medical research [30].
NARPD National Association for the Relief of Paget's Dis-
ease. A support group for people with Paget's disease, their
family and carers [31].
Non-familial Paget's disease Paget's disease that only
affects one person in a family.
PDFR Paget's Disease Family Register. A study led by Prof
Ralston, investigating the genetics of Paget's disease.
PRISM A trial led by Prof Ralston and co-ordinated by Dr
Langston, investigating the treatment of Paget's disease.
Proband Initial person of contact within a family who has
Paget's disease
Relative  A relative of a proband (i.e. brother, sister,
mother, father, grandmother, grandfather, son, daughter,
grandson, grand daughter, nephew, niece)
SF-36 A questionnaire that measures general health, and
quality of life.
SQSTM1 Sequestosome 1 [RNA NM_003900]. One of the
genes identified that, when 'faulty', causes Paget's disease.
SRM The Self Regulation Model. A psychological theory
that aims to identify how people perceive their illness.
TPB The Theory of Planned Behaviour. A psychological
theory that aims to identify predictors of behaviour using
a defined framework.
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